Founded in 2001. Listed on the Taipei OTC. Built around glycobiology.

Specialist in monoclonal antibody development and preclinical biopharmaceutical strategy. Long tenure at Amgen contributing to oncology and neuroscience drug discovery, including co-authorship on the foundational in vitro characterization of epratuzumab — a humanized anti-CD22 IgG1 monoclonal antibody (Clin Cancer Res, 2003). Founder and CEO of Josette Carnahan Consulting, LLC. Ph.D. in Molecular and Cellular Biology (developmental neuroscience), Université Louis Pasteur, Strasbourg.

Over three decades in Japanese pharmaceutical non-clinical development, spanning toxicology, regulatory affairs, and CTD/eCTD submission. Previously General Manager of Non-Clinical Development at Fujifilm Kyowa Kirin Biologics, leading non-clinical programs for biosimilar antibody products, and earlier a Non-Clinical Development manager at Kyowa-Hakko Kirin. Began his career at Kirin Brewery's pharmaceutical division as a toxicology study director and chief pathologist. Since 2016, an independent consultant across small-molecule, antibody (including biosimilars), nucleic-acid, and cell-and-gene-therapy modalities. Licensed veterinarian (DVM, 1987); M.S. in pathology, Nippon Veterinary and Zootechnical College.

Over 35 years in biopharmaceutical CMC development and manufacturing. Previously Vice President of Manufacturing at Coulter Pharmaceutical (leading CMC for Bexxar™) and Vice President of Process Development at Corixa Corporation. Earlier roles at Genentech (Protropin™, Activase™) and Immunex (Leukine™, Enbrel™). Has supported CMC development from preclinical to post-registration stage for clients across North America, Europe, and Asia-Pacific. B.S. in Fermentation Science, University of California at Davis.

Decades of translational medicine and oncology drug development across pharmaceutical, biotech, and academic settings. Former Science Manager in Medical Affairs Oncology at Otsuka Pharmaceutical, contributing to clinical development of cancer therapeutics including the BCR-ABL tyrosine kinase inhibitor ponatinib (Iclusig®). Former President & CEO of Argenes, Inc. Has also served as Specially Appointed Associate Professor and Vice Director at Hokkaido University's Clinical Research and Development Center. D.V.M. and Ph.D., University of Tokyo (1995).

Over 20 years of oncology drug development experience spanning clinical evaluation, strategic trial design (Phase I–III), and project management. Previous senior roles at PharmaEngine (VP, Translational Science) and AstraZeneca Taiwan (Manager, Clinical Research). M.S. in Pharmaceutical Sciences (Pharmacotherapeutics), St. John's University School of Pharmacy.

Twenty years of antibody and hematopoietic stem cell research at Kirin Brewery's pharmaceutical division (now Kyowa Kirin) in Takasaki, Gunma, Japan, where he led patent programs for HSC expansion methods and the AMM2 anti-Mpl monoclonal antibody. Author of foundational work on thrombopoietin signaling and HSC bone marrow niche biology published in Blood, PNAS, and Stem Cells and Development. Collaborated internationally with the University of Michigan and the University of Tsukuba on in vivo HSC niche imaging.

Over 30 years of pharmaceutical and biotech business development experience, with a track record of more than 150 completed transactions ranging from preclinical candidate licensing to multinational acquisitions. Founder of Pullan Consulting (since 2006), advising biotech and pharmaceutical clients in the US, Europe, and Asia on partnering strategy, valuation, and negotiation. Previously Director of Licensing at Amgen (oncology & hematology), VP of Business Development at Kosan Biosciences, and led early in-licensing at AstraZeneca. Joined the Supervisory Board of NLC Health Ventures in June 2024. Frequent speaker at BIO-Europe and negotiation trainer at EBD Academy. Ph.D. in Biochemistry, UC Riverside; B.S. in Chemistry, University of Utah.

Site-specific bioconjugation and ADC chemistry specialist. Co-founder of Acrigen Biosciences (Berkeley, CA), developing precision gene editing therapeutics. Previously co-founded Redwood Bioscience with Carolyn Bertozzi (2022 Nobel Laureate in Chemistry), where he developed the SMARTag® site-specific ADC conjugation platform — acquired by Catalent Pharma Solutions in 2014, where he subsequently served as Global Head of R&D, Chemical Biology. Author of over 45 peer-reviewed publications and inventor on more than 30 patents. Ph.D. in Chemistry, UC Berkeley (Bertozzi lab, Chevron Fellow).

Over 30 years in nonclinical toxicology and preclinical drug development, with extensive regulatory experience across US FDA, US EPA, OECD, and Japan MHLW GLP frameworks. Diplomate of the American Board of Toxicology (DABT). Has authored or reviewed over 300 regulatory submissions following ICH guidelines. Previous research and management roles at MPI Research, Charles River Laboratories, Arkansas Children's Hospital, and the US FDA. Past President of the Society of Toxicology's Toxicologists of African Origin Special Interest Group.

Twenty years of biopharmaceutical CMC and process development in monoclonal antibodies and recombinant proteins, from early-stage discovery to commercial life-cycle management. Previously General Manager of the Production & Development Center at Fujifilm Kyowa Kirin Biologics. Has participated in JPMA's Biopharmaceutical Technology Working Committee (2015–2019) and contributed as an ICH Q12 EWG expert. Visiting Professor at Gunma University. Ph.D., Tokyo Institute of Technology.